Phase I trial of gemcitabine (GEM) infused at fixed-dose rate (FDR) with high-dose docetaxel/melphalan/carboplatin (GEM-DMC) and autologous stem-cell transplant (ASCT)
Year: 2007
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Y. Nieto, J. Rifon, J. Perez-Calvo, A. Zafra, L. Zufia, A. Viudez, S. Viteri, O. Sayan, M. Hernandez, A. Aldaz
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2223518707